Stock Details
BMY is Bristol-Myers Squibb Company's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 74.39$. Average daily volumn in 3 months 9.74M. Market cap 171.96B



Stock symbol : BMY. Exchange : NYSE. Currency : USD
Lastest price : 80.88$. Total volume : 9.92M. Market state PRE
Click reload if you want to check the lastest price on market!!!

Bristol-Myers Squibb Company (BMY)
Last Price
80.88$
Change
0.60
Volume
9.92M

Previous Close80.28
Open80.48
Day Range80.05-81.43
Bid80.36 x 800
Ask81.44 x 1.3k
Volume9.92M
Average Volume9.74M
Market Cap171.96B
Beta0.39
52 Week Range55.76-81.43
Trailing P/E26.35
Foward P/E10.19
Dividend (Yield %)2.73%
Ex-Dividend Date2022-10-06



Financial Details


According to Bristol-Myers Squibb Company's financial reports the company's revenue in 2021 were 46.38B an increase( +9.52%) over the years 2020 revenue that were of 42.52B. In 2021 the company's total earnings were 6.99B while total earnings in 2020 were -9.02B(-166.67%).


Loading ...



Organization

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indi... cations; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Market Cap:
171.96B
Revenue:
46.38B
Total Assets:
109.31B
Total Cash:
13.98B



News about "Bristol-Myers Squibb Company"

is-bristol-myers-squibb-company-nysebmy-trading-at-a-37-discount-image

Is Bristol-Myers Squibb Company (NYSE:BMY) Trading At A 37% Discount?

Source from : YAHOO!Finance - 3 days ago

Today we will run through one way of estimating the intrinsic value of Bristol-Myers Squibb Company ( NYSE:BMY ) ...See details»


a-note-on-bristol-myers-squibb-companys-nysebmy-roe-and-debt-to-equity-image

A Note On Bristol-Myers Squibb Company's (NYSE:BMY) ROE and Debt To Equity

Source from : YAHOO!Finance - 7 days ago

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article ...See details»


bristol-myers-squibb-share-price-growth-in-2022-best-for-a-decade-but-2023-could-better-it-image

Bristol Myers Squibb: Share Price Growth In 2022 Best For A Decade - But 2023 Could Better It

Source from : Seeking Alpha - 3 days ago

Bristol Myers Squibb is a pharmaceutical powerhouse after its Celgene acquisition. See why I think there is another 30% upside to BMY stock.See details»


Bristol-Myers Squibb Is Still An Attractive Addition To Your Dividend Growth Portfolio

Source from : Seeking Alpha - 5 days ago

Shares of Bristol-Myers Squibb Company are up 28% year to date. Bristol-Myers Squibb is still attractively valued. Investors should consider Bristol-Myers Squibb for their dividend growth portfolio.See details»


With 75% institutional ownership, Bristol-Myers Squibb Company (NYSE:BMY) is a favorite amongst the big guns

Source from : Yahoo - 11 days ago

Every investor in Bristol-Myers Squibb Company (NYSE:BMY) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are institutions with 75% ...See details»


Bristol Myers Squibb Threatens New Rules Will Hinder Drug Production

Source from : MSN - 11 days ago

Now, Bristol Myers Squibb is threatening that the IRA's reforms ... CEO Giovanni Caforio told the Financial Times on Saturday. The company would be joining Eli Lilly, which earlier this month ...See details»


Envisagenics Announces Research Collaboration with Bristol Myers Squibb

Source from : Business Insider - 3 days ago

Collaboration will leverage Envisagenics' SpliceCoreยฎ AI platform for accelerated discovery and development of oncology therapeutic candidatesNEW ...See details»


Is There An Opportunity With Bristol-Myers Squibb Company's (NYSE:BMY) 40% Undervaluation?

Source from : AOL - 20 days ago

Today we will run through one way of estimating the intrinsic value of Bristol-Myers Squibb Company (NYSE:BMY) by taking the forecast future cash flows of the company and discounting them back to ...See details»


Why Bristol-Myers Squibb Company (NYSE: BMY) Is A Great Stock Pick For Momentum Investors

Source from : stocksregister - 13 days ago

Bristol-Myers Squibb Company (NYSE:BMY) shares, rose in value on Friday, November 18, with the stock price up by 0.19% to the previous dayโ€™s close as strong demand from buyers drove the stock to ...See details»


Bristol-Myers Squibb Company (BMY) Just Got Our Attention

Source from : newsheater - 2 years ago

Bristol-Myers Squibb Company (NYSE:BMY) went down by -0.13% from its latest closing price compared to the recent 1-year high of $81.17. The companyโ€™s stock price has collected 2.18% of gains in the ...See details»


Is Bristol Myers Squibb Stock a Buy With Its New-Product Sales Soaring?

Source from : Nasdaq - 1 month ago

Bristol Myers Squibb CEO Giovanni Caforio noted in the Q3 results press release that the company has launched nine new products over the last three years, with three of them coming in 2022.See details»


How Good Is Bristol-Myers Squibb Company (NYSE:BMY), When It Comes To ROE?

Source from : Yahoo! Sports - 1 month ago

By way of learning-by-doing, we'll look at ROE to gain a better understanding of Bristol-Myers Squibb Company (NYSE:BMY). Return on equity or ROE is a key measure used to assess how efficiently a ...See details»


Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial

Source from : Stockhouse - 1 month ago

Creating a Better Future for People with Cancer Bristol Myers Squibb is inspired by a single vision โ€” transforming people’s lives through science. The goal of the ...See details»


Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases

Source from : newsroom.businesswire.com - 10 days ago

New data from our multiple myeloma portfolio across targets and molecular approaches show significant progress toward our goal of transforming the treatment paradigm and improving outcomes for ...See details»